{"id":198484,"date":"2026-09-01T12:22:08","date_gmt":"2026-09-01T12:22:08","guid":{"rendered":"https:\/\/www.europesays.com\/cz\/198484\/"},"modified":"2026-09-01T12:22:08","modified_gmt":"2026-09-01T12:22:08","slug":"uspech-ceske-prevence-evropa-ji-obdivuje-tretina-muzu-s-podezrenim-na-nador-z-ni-ale-vypadne","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/cz\/198484\/","title":{"rendered":"\u00dasp\u011bch \u010desk\u00e9 prevence? Evropa j\u00ed obdivuje, t\u0159etina mu\u017e\u016f s podez\u0159en\u00edm na n\u00e1dor z n\u00ed ale vypadne"},"content":{"rendered":"

\u010cesk\u00fd program \u010dasn\u00e9ho z\u00e1chytu karcinomu prostaty, kter\u00fd ministerstvo zdravotnictv\u00ed spustilo v lednu 2024, oslovil b\u011bhem prvn\u00edch dvou let v\u00edce ne\u017e 310 tis\u00edc mu\u017e\u016f. \u010cesko se d\u00edky n\u011bmu \u0159ad\u00ed mezi prvn\u00ed evropsk\u00e9 zem\u011b, kter\u00e9 mohou p\u0159edstavit konkr\u00e9tn\u00ed v\u00fdsledky organizovan\u00e9ho screeningu v celost\u00e1tn\u00edm m\u011b\u0159\u00edtku. Ministerstvo to uvedlo v \u00fater\u00fd v tiskov\u00e9 zpr\u00e1v\u011b<\/a>. Probl\u00e9m v\u0161ak je, \u017ee zhruba t\u0159etina mu\u017e\u016f s podez\u0159en\u00edm na n\u00e1dor nedoraz\u00ed na dal\u0161\u00ed vy\u0161et\u0159en\u00ed k urologovi, kter\u00fd by diagn\u00f3zu potvrdil, \u010di vyvr\u00e1til.\u00a0<\/p>\n

\u201eKarcinom prostaty pat\u0159\u00ed mezi nej\u010dast\u011bj\u0161\u00ed n\u00e1dorov\u00e1 onemocn\u011bn\u00ed,\u201c uvedl na \u00fatern\u00ed tiskov\u00e9 konferenci ministr zdravotnictv\u00ed Adam Vojt\u011bch (za ANO). Ro\u010dn\u011b se podle n\u011bj diagn\u00f3za potvrd\u00ed asi u 10 tis\u00edc mu\u017e\u016f, 1 500 na ni zem\u0159e. Podle odborn\u00edk\u016f je za n\u00e1r\u016fstem jej\u00edho po\u010dtu jak st\u00e1rnut\u00ed populace, tak lep\u0161\u00ed diagnostika. V \u010cesku ov\u0161em st\u00e1le \u017eije kolem osmi \u010di dev\u00edti tis\u00edci mu\u017e\u016f, kte\u0159\u00ed o sv\u00e9 rakovin\u011b prostaty zat\u00edm nev\u00ed.<\/p>\n

Jen 64 % mu\u017e\u016f doraz\u00ed k urologovi do \u0161esti m\u011bs\u00edc\u016f<\/p>\n

Zhruba dva tis\u00edce mu\u017e\u016f na ni p\u0159i\u0161lo d\u00edky vy\u0161et\u0159en\u00ed v r\u00e1mci screeningu, tedy krevn\u00edho testu, kter\u00fd jim l\u00e9ka\u0159 nab\u00eddl na z\u00e1klad\u011b v\u011bku, nikoliv pot\u00ed\u017e\u00ed. Celkem jich oslovili p\u0159es 310 tis\u00edc, z nich v\u00edce ne\u017e 26 tis\u00edc m\u011blo vy\u0161\u0161\u00ed hladinu prostatistick\u00e9ho specifick\u00e9ho antigenu (PSA). Pr\u00e1v\u011b ten m\u016f\u017ee signalizovat n\u00e1dor. \u201eJen 64 % z nich ale dorazilo k urologovi do \u0161esti m\u011bs\u00edc\u016f,\u201c \u0159ekl p\u0159ednosta Urologick\u00e9 kliniky 2. l\u00e9ka\u0159sk\u00e9 fakulty Univerzity Karlovy a Fakultn\u00ed nemocnice Motol a Homolka Marek Babjuk.<\/p>\n

\u010cesk\u00e1 urologick\u00e1 spole\u010dnost Jana Evangelisty Purkyn\u011b podle jej\u00edho p\u0159edsedy Romana Zachovala analyzuje, pro\u010d tomu tak je. \u201eJestli to je bari\u00e9ra, nap\u0159\u00edklad obava, na stran\u011b pacient\u016f, nevy\u0161le je tam praktik nebo je t\u0159eba nedostate\u010dn\u00e1 s\u00ed\u0165 urolog\u016f v n\u011bjak\u00e9 lokalit\u011b,\u201c vysv\u011btlil.<\/p>\n

Program pln\u011b hrazen\u00fd ze zdravotn\u00edho poji\u0161t\u011bn\u00ed je ur\u010den mu\u017e\u016fm ve v\u011bku 50 a\u017e 69 let. Jeho c\u00edlem je vyhled\u00e1vat klinicky v\u00fdznamn\u00e9 n\u00e1dory prostaty v dob\u011b, kdy je mo\u017en\u00e9 onemocn\u011bn\u00ed \u00fa\u010dinn\u011b l\u00e9\u010dit, a sou\u010dasn\u011b omezovat zbyte\u010dn\u00e1 invazivn\u00ed vy\u0161et\u0159en\u00ed. Mu\u017ei se mohou na mo\u017enost zapojen\u00ed zeptat sv\u00e9ho praktick\u00e9ho l\u00e9ka\u0159e nebo urologa. Screening lze jednodu\u0161e zah\u00e1jit p\u0159i b\u011b\u017en\u00e9 preventivn\u00ed prohl\u00eddce u praktick\u00e9ho l\u00e9ka\u0159e.<\/p>\n

P\u0159echod od nahodil\u00e9ho testov\u00e1n\u00ed PSA k organizovan\u00e9mu programu<\/p>\n

Zku\u0161enosti a v\u00fdsledky z prvn\u00edho roku fungov\u00e1n\u00ed screeningu p\u0159inesl \u010dl\u00e1nek Implementation and First Results of the Czech Nationwide Prostate Cancer Screening Pilot Programme<\/a>. Publikoval jej mezin\u00e1rodn\u00ed odborn\u00fd \u010dasopis European Urology Open Science. <\/p>\n

\u201eJde o v\u016fbec prvn\u00ed celopopula\u010dn\u00ed hodnocen\u00ed\u00a0celost\u00e1tn\u00edho organizovan\u00e9ho programu screeningu karcinomu prostaty ve st\u0159edn\u00ed Evrop\u011b. Publikace v\u00a0presti\u017en\u00edm \u010dasopise tak potvrzuje, \u017ee p\u0159echod od nahodil\u00e9ho testov\u00e1n\u00ed PSA k organizovan\u00e9mu programu s jasn\u011b definovan\u00fdm algoritmem je v podm\u00ednk\u00e1ch \u010desk\u00e9ho zdravotnictv\u00ed provediteln\u00fd a vede u\u017e nyn\u00ed k lep\u0161\u00edmu dodr\u017eov\u00e1n\u00ed doporu\u010den\u00fdch diagnostick\u00fdch postup\u016f,\u201c napsalo ministerstvo v tiskov\u00e9 zpr\u00e1v\u011b. <\/p>\n

\u010cl\u00e1nek \u201evych\u00e1z\u00ed v dob\u011b, kdy Evropsk\u00e1 unie doporu\u010duje \u010dlensk\u00fdm st\u00e1t\u016fm zav\u00e1d\u011bt pilotn\u00ed programy organizovan\u00e9ho screeningu karcinomu prostaty. \u010cesk\u00fd program tak pat\u0159\u00ed mezi prvn\u00ed, kter\u00e9 u\u017e mohou prezentovat konkr\u00e9tn\u00ed v\u00fdsledky z re\u00e1ln\u00e9 klinick\u00e9 praxe. A to na \u00farovni cel\u00e9 c\u00edlov\u00e9 populace,\u201c sd\u011blil resort.<\/p>\n

\u201eSkute\u010dnost, \u017ee prvn\u00ed v\u00fdsledky \u010desk\u00e9ho programu z\u00edsk\u00e1vaj\u00ed pozornost tak\u00e9 v mezin\u00e1rodn\u00edm odborn\u00e9m prost\u0159ed\u00ed, potvrzuje v\u00fdznam t\u00e9to cesty nejen pro \u010ceskou republiku, ale i pro dal\u0161\u00ed evropsk\u00e9 zem\u011b, kter\u00e9 se mohou na\u0161\u00edm p\u0159\u00edstupem inspirovat. Tento i dal\u0161\u00ed organizovan\u00e9 programy prevence budou nad\u00e1le jednou z\u00a0hlavn\u00edch priorit ministerstva zdravotnictv\u00ed,\u201c\u00a0uvedl Vojt\u011bch.<\/p>\n

Mohlo by v\u00e1s zaj\u00edmat<\/p>\n


\n \"\"
\n <\/a><\/p>\n

Vyhnout se zbyte\u010dn\u00e9 diagnostice<\/p>\n

Prvn\u00edm krokem screeningov\u00e9ho programu je odb\u011br krve ke stanoven\u00ed hladiny PSA. Diagnostick\u00fd postup se pot\u00e9 \u0159\u00edd\u00ed hodnotou PSA a v\u00fdsledky navazuj\u00edc\u00edch odborn\u00fdch vy\u0161et\u0159en\u00ed. P\u0159i n\u00edzk\u00e9 hodnot\u011b PSA se dal\u0161\u00ed kontrola PSA doporu\u010duje s del\u0161\u00edm \u010dasov\u00fdm odstupem.<\/p>\n

Hodnota od 3 \u00b5g\/l se pova\u017euje za rizikovou. Sama o sob\u011b neznamen\u00e1 diagn\u00f3zu karcinomu prostaty, ale doporu\u010den\u00ed k podrobn\u011bj\u0161\u00edmu vy\u0161et\u0159en\u00ed certifikovan\u00fdm urologem a p\u0159\u00edpadn\u011b k n\u00e1vazn\u00e9 magnetick\u00e9 rezonanci \u010di biopsii prostaty. B\u011bhem prvn\u00edho roku trv\u00e1n\u00ed programu se v\u00fdznamn\u011b zv\u00fd\u0161ilo vyu\u017e\u00edv\u00e1n\u00ed magnetick\u00e9 rezonance p\u0159ed biopsi\u00ed prostaty, co\u017e podle ministerstva p\u0159edstavuje jeden z hlavn\u00edch ukazatel\u016f kvalitn\u011bj\u0161\u00ed a p\u0159esn\u011bj\u0161\u00ed diagnostiky.<\/p>\n

\u201eEvropa dnes hled\u00e1 zp\u016fsob, jak zachytit karcinom prostaty v\u010das a p\u0159itom se vyhnout zbyte\u010dn\u00e9 diagnostice. \u010cesk\u00fd program ukazuje, \u017ee to je mo\u017en\u00e9. Nespol\u00e9h\u00e1me pouze na hodnotu PSA, ale na cel\u00fd navazuj\u00edc\u00ed diagnostick\u00fd postup, kter\u00fd vyu\u017e\u00edv\u00e1 modern\u00ed zobrazovac\u00ed metody a pom\u00e1h\u00e1 odli\u0161it mu\u017ee, kte\u0159\u00ed skute\u010dn\u011b pot\u0159ebuj\u00ed dal\u0161\u00ed vy\u0161et\u0159en\u00ed,\u201c\u00a0vysv\u011btlil Babjuk. <\/p>\n

\u201eV dob\u011b, kdy \u0159ada evropsk\u00fdch zem\u00ed teprve p\u0159ipravuje vlastn\u00ed pilotn\u00ed programy, p\u0159edstavuj\u00ed \u010desk\u00e9 zku\u0161enosti cenn\u00fd zdroj poznatk\u016f pro dal\u0161\u00ed rozvoj organizovan\u00e9ho screeningu v\u00a0Evrop\u011b. Na\u0161e dosavadn\u00ed v\u00fdsledky rovn\u011b\u017e potvrzuj\u00ed v\u00fdznam takzvan\u00fdch pilotn\u00edch projekt\u016f. Ty poskytovatel\u016fm p\u00e9\u010de d\u00e1vaj\u00ed \u010das a prostor se na tak n\u00e1ro\u010dn\u00fd program dob\u0159e p\u0159ipravit,\u201c\u00a0zd\u016fraznil \u0159editel \u00dastavu zdravotnick\u00fdch informac\u00ed a statistiky Ladislav Du\u0161ek.<\/p>\n

V\u00edce mu\u017e\u016f testovan\u00fdch na PSA<\/p>\n

Testov\u00e1n\u00ed PSA bylo v \u010cesk\u00e9 republice roz\u0161\u00ed\u0159en\u00e9 u\u017e p\u0159ed spu\u0161t\u011bn\u00edm programu. \u010casto v\u0161ak prob\u00edhalo mimo organizovan\u00fd syst\u00e9m a bez jednotn\u011b nastaven\u00e9 n\u00e1vazn\u00e9 p\u00e9\u010de. Zat\u00edmco p\u0159ed zah\u00e1jen\u00edm programu se vy\u0161et\u0159en\u00edm PSA u mu\u017e\u016f ve v\u011bku 50\u201369 let pohybovalo na \u00farovni 45-47 %, v\u00a0roce 2025 u\u017e p\u0159es\u00e1hlo hodnotu 57,0 %.<\/p>\n

\u201e\u010cesk\u00fd pilotn\u00ed program p\u0159in\u00e1\u0161\u00ed n\u011bkolik velmi zaj\u00edmav\u00fdch prvk\u016f, ze kter\u00fdch se mohou u\u010dit i dal\u0161\u00ed evropsk\u00e9 zem\u011b. Oce\u0148ujeme zejm\u00e9na zp\u016fsob, jak\u00fdm se poda\u0159ilo za\u010dlenit screeningov\u00fd algoritmus do u\u017e existuj\u00edc\u00edch preventivn\u00edch prohl\u00eddek. Pr\u00e1v\u011b tento p\u0159\u00edstup pova\u017eujeme za d\u016fle\u017eit\u00fd z hlediska proveditelnosti i p\u0159ijatelnosti programu pro zdravotnick\u00fd syst\u00e9m i samotn\u00e9 pacienty,\u201c\u00a0uvedli profesor Hendrik Van Poppel, p\u0159edseda sekce zdravotn\u00ed politiky Evropsk\u00e9 urologick\u00e9 asociace, a profesorka Monique Roobol-Boutsov\u00e1, v\u011bdeck\u00e1 koordin\u00e1torka pilotn\u00edch projekt\u016f screeningu karcinomu prostaty Evropsk\u00e9 urologick\u00e9 asociace.<\/p>\n

Screening rakoviny prostaty v \u010d\u00edslech<\/p>\n

U rakoviny prostaty diagnostikovan\u00e9 v \u010dasn\u00e9m stadiu je \u0161ance na vyl\u00e9\u010den\u00ed a dlouhodob\u00e9 p\u0159e\u017eit\u00ed n\u00e1sobn\u011b vy\u0161\u0161\u00ed. P\u011btilet\u00e9 relativn\u00ed p\u0159e\u017eit\u00ed u v\u010das zachycen\u00fdch n\u00e1dor\u016f \u010din\u00ed 100 %. Pokud se onemocn\u011bn\u00ed zachyt\u00ed v\u00a0pokro\u010dil\u00e9m IV. stadiu, dosahovan\u00e9 p\u011btilet\u00e9 p\u0159e\u017eit\u00ed m\u00edrn\u011b p\u0159ekra\u010duje 50 %.<\/p>\n

C\u00edlovou populac\u00ed pro \u010desk\u00fd program screeningu karcinomu prostaty jsou mu\u017ei bez diagn\u00f3zy karcinomu prostaty v\u00a0osobn\u00ed anamn\u00e9ze, ve v\u011bku 50-69 let v\u010detn\u011b. Program \u010dasn\u00e9ho z\u00e1chytu karcinomu prostaty za\u010dal v \u010cR 1. ledna 2024.<\/p>\n

Za prvn\u00ed dva roky bylo osloveno v\u00edce ne\u017e 310 tis\u00edc mu\u017e\u016f. Pod\u00edl mu\u017e\u016f, u kter\u00fdch se zjistila zv\u00fd\u0161en\u00e1 hodnota PSA, dosahuje 8,7 % (v\u00edce ne\u017e 26,5 tis\u00edce mu\u017e\u016f).<\/p>\n

Velmi v\u00fdznamn\u00fdm pozitivem je vysok\u00e1 ochota osloven\u00fdch mu\u017e\u016f k\u00a0\u00fa\u010dasti ve screeningu, kter\u00e1 dosahuje 99,1 %. Probl\u00e9mem je, navazuj\u00edc\u00ed vy\u0161et\u0159en\u00ed u urologa podstoupilo do \u0161esti m\u011bs\u00edc\u016f jen asi p\u0159ibli\u017en\u011b 64 % mu\u017e\u016f se zv\u00fd\u0161enou hodnotou PSA.<\/p>\n

Pr\u016fb\u011b\u017en\u00e9 v\u00fdsledky programu dokl\u00e1daj\u00ed dosavadn\u00ed z\u00e1chyt 2\u00a0079 karcinom\u016f prostaty, kter\u00e9 se v\u00a0drtiv\u00e9 v\u011bt\u0161in\u011b poda\u0159\u00ed uspokojiv\u011b vyl\u00e9\u010dit. <\/p>\n","protected":false},"excerpt":{"rendered":"\u010cesk\u00fd program \u010dasn\u00e9ho z\u00e1chytu karcinomu prostaty, kter\u00fd ministerstvo zdravotnictv\u00ed spustilo v lednu 2024, oslovil b\u011bhem prvn\u00edch dvou let…\n","protected":false},"author":2,"featured_media":198485,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[3],"tags":[646,45534,109,108,106,45535,45536,45537,26603,45538,2811,45539,3487,3489,10258],"class_list":["post-198484","post","type-post","status-publish","format-standard","has-post-thumbnail","category-evropa","tag-adam-vojtech","tag-ceska-urologicka-spolecnost","tag-europa","tag-europe","tag-evropa","tag-karcinom-prostaty","tag-ladislav-dusek","tag-marek-babjuk","tag-ministerstvo-zdravotnictvi","tag-prostata","tag-rakovina","tag-roman-zachoval","tag-screening","tag-screeningove-programy","tag-urologie"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@cz\/117195764667832566","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/198484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/comments?post=198484"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/198484\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media\/198485"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media?parent=198484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/categories?post=198484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/tags?post=198484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}